Morgan Stanley raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $130 from $123 and keeps an Overweight rating on the shares. The firm Q4 report was “uneventful” as sales were previously announced and 2026 guidance was reiterated, implying strong trends for the commercial business, says the analyst, who adds that “multiple meaningful catalysts” remain on track for 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target lowered to $128 from $130 at RBC Capital
- Mirum Pharmaceuticals price target raised to $125 from $98 at Stifel
- Mirum Pharmaceuticals: Livmarli-Driven Outperformance and Catalyst-Rich Pipeline Underpin Buy Rating
- Mirum Pharmaceuticals price target lowered to $132 from $140 at Citizens
- Mirum Pharmaceuticals files to sell 8.96M shares of common stock for holders